Literature DB >> 15452841

Cardiac and skeletal muscle involvement in myotonic dystrophy type 2 (DM2): a quantitative 31P-MRS and MRI study.

Christiane Schneider-Gold1, Meinrad Beer, Herbert Köstler, Stefan Buchner, Jörn Sandstede, Dietbert Hahn, Klaus V Toyka.   

Abstract

In myotonic dystrophy type 2 (DM2/PROMM), cardiac muscle involvement is usually more benign than in DM1, but clinically severe cardiomyopathy has been reported in some patients. Using a novel method of magnetic resonance spectroscopy (MRS), we examined the left ventricular myocardium and the left gastrocnemius muscle in 11 unselected DM2/PROMM patients without overt cardiac disease. Data on cardiac morphology and function were obtained by gradient echo two-dimensional cine magnetic resonance imaging (MRI); no significant differences were found between DM2 patients and healthy controls, but using a median split approach older patients showed mildly increased left ventricular (LV) volumes, i.e., 59% increase of end-systolic volume index (ESVI) and 35% increase of end-diastolic volume index (EDVI), and an increase of LV mass (26%). On cardiac MRS, DM2/PROMM patients showed a reduction of phosphocreatine (PCr) and adenosine triphosphate (ATP) by 25 and 20% compared to matched healthy controls. No significant differences were found between younger and older patients. In skeletal muscle of the DM2 patients, no significant decrease of PCr and ATP concentrations was found. However, in older patients, who commonly show overt hip flexor muscle weakness, we observed reduced values for PCr and ATP. Our MRS and MRI findings reveal evidence for subclinical cardiomyopathy in DM2/PROMM patients without overt heart disease. Future prospective studies are needed to clarify the risk of developing overt cardiac disease in DM2 and to define prognostic factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452841     DOI: 10.1002/mus.20156

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  6 in total

Review 1.  Recent advances in myotonic dystrophy type 2.

Authors:  Christina M Ulane; Sarah Teed; Jacinda Sampson
Journal:  Curr Neurol Neurosci Rep       Date:  2014-02       Impact factor: 5.081

2.  Severe dilated cardiomyopathy in a patient with myotonic dystrophy type 2 and homozygous repeat expansion in ZNF9.

Authors:  Teresa M Lee; Mathew S Maurer; Izabela Karbassi; Corey Braastad; Sat D Batish; Wendy K Chung
Journal:  Congest Heart Fail       Date:  2011-11-03

3.  Circulating Irisin Is Reduced in Male Patients with Type 1 and Type 2 Myotonic Dystrophies.

Authors:  Elena Dozio; Elena Passeri; Rosanna Cardani; Stefano Benedini; Carmen Aresta; Rea Valaperta; Massimiliano Corsi Romanelli; Giovanni Meola; Valeria Sansone; Sabrina Corbetta
Journal:  Front Endocrinol (Lausanne)       Date:  2017-11-14       Impact factor: 5.555

Review 4.  Multinuclear MRI in Drug Discovery.

Authors:  Dorota Bartusik-Aebisher; Zuzanna Bober; Jolanta Zalejska-Fiolka; Aleksandra Kawczyk-Krupka; David Aebisher
Journal:  Molecules       Date:  2022-10-01       Impact factor: 4.927

5.  Cardiac high-energy phosphate metabolism alters with age as studied in 196 healthy males with the help of 31-phosphorus 2-dimensional chemical shift imaging.

Authors:  Regina Esterhammer; Gert Klug; Christian Wolf; Agnes Mayr; Sebastian Reinstadler; Hans-Josef Feistritzer; Bernhard Metzler; Michael F H Schocke
Journal:  PLoS One       Date:  2014-06-18       Impact factor: 3.240

Review 6.  Role of cardiac magnetic resonance in the evaluation of dilated cardiomyopathy: diagnostic contribution and prognostic significance.

Authors:  Marco Francone
Journal:  ISRN Radiol       Date:  2014-02-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.